139 related articles for article (PubMed ID: 20163277)
1. Ertapenem.
Congeni BL
Expert Opin Pharmacother; 2010 Mar; 11(4):669-72. PubMed ID: 20163277
[TBL] [Abstract][Full Text] [Related]
2. Ertapenem.
Parakh A; Krishnamurthy S; Bhattacharya M
Kathmandu Univ Med J (KUMJ); 2009; 7(28):454-60. PubMed ID: 20502094
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of ertapenem: review of recent studies.
Wexler HM
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii11-21. PubMed ID: 15150179
[TBL] [Abstract][Full Text] [Related]
4. Properties and potential of ertapenem.
Livermore DM; Sefton AM; Scott GM
J Antimicrob Chemother; 2003 Sep; 52(3):331-44. PubMed ID: 12917243
[TBL] [Abstract][Full Text] [Related]
5. Carbapenems: a potent class of antibiotics.
Nicolau DP
Expert Opin Pharmacother; 2008 Jan; 9(1):23-37. PubMed ID: 18076336
[TBL] [Abstract][Full Text] [Related]
6. Comparative review of the carbapenems.
Zhanel GG; Wiebe R; Dilay L; Thomson K; Rubinstein E; Hoban DJ; Noreddin AM; Karlowsky JA
Drugs; 2007; 67(7):1027-52. PubMed ID: 17488146
[TBL] [Abstract][Full Text] [Related]
7. Ertapenem for the treatment of extended-spectrum beta-lactamase-producing Gram-negative bacterial infections.
Teng CP; Chen HH; Chan J; Lye DC
Int J Antimicrob Agents; 2007 Oct; 30(4):356-9. PubMed ID: 17631986
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians.
Nix DE; Majumdar AK; DiNubile MJ
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii23-8. PubMed ID: 15150180
[TBL] [Abstract][Full Text] [Related]
9. [Available carbapenems: Properties and differences].
Martínez MJ; García MI; Sánchez EG; Sánchez JE
Enferm Infecc Microbiol Clin; 2010 Sep; 28 Suppl 2():53-64. PubMed ID: 21130931
[TBL] [Abstract][Full Text] [Related]
10. Ertapenem: a Group 1 carbapenem with distinct antibacterial and pharmacological properties.
Hammond ML
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii7-9. PubMed ID: 15150178
[TBL] [Abstract][Full Text] [Related]
11. Carbapenems in the USA: focus on doripenem.
Lister PD
Expert Rev Anti Infect Ther; 2007 Oct; 5(5):793-809. PubMed ID: 17914914
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis: ertapenem for complicated intra-abdominal infections.
Falagas ME; Peppas G; Makris GC; Karageorgopoulos DE; Matthaiou DK
Aliment Pharmacol Ther; 2008 May; 27(10):919-31. PubMed ID: 18266994
[TBL] [Abstract][Full Text] [Related]
13. Ertapenem: a new opportunity for outpatient parenteral antimicrobial therapy.
Tice AD
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii83-6. PubMed ID: 15150187
[TBL] [Abstract][Full Text] [Related]
14. Redefining penems.
Dalhoff A; Janjic N; Echols R
Biochem Pharmacol; 2006 Mar; 71(7):1085-95. PubMed ID: 16413506
[TBL] [Abstract][Full Text] [Related]
15. Parenteral carbapenems.
Shah PM
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():175-80. PubMed ID: 18154543
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of ertapenem for consolidation therapy of extended-spectrum beta-lactamase-producing gram-negative infections: a case series report.
Berg ML; Crank CW; Philbrick AH; Hayden MK
Ann Pharmacother; 2008 Feb; 42(2):207-12. PubMed ID: 18230703
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of ertapenem in the treatment of serious infections caused by Enterobacteriaceae: analysis of pooled clinical trial data.
Gesser RM; McCarroll K; Teppler H; Woods GL
J Antimicrob Chemother; 2003 May; 51(5):1253-60. PubMed ID: 12697633
[TBL] [Abstract][Full Text] [Related]
18. Doripenem monohydrate, a broad-spectrum carbapenem antibiotic.
Matthews SJ; Lancaster JW
Clin Ther; 2009 Jan; 31(1):42-63. PubMed ID: 19243706
[TBL] [Abstract][Full Text] [Related]
19. Clinical response to ertapenem in severe community-acquired pneumonia: a retrospective series in an elderly population.
Murcia JM; González-Comeche J; Marín A; Barberán J; Granizo JJ; Aguilar L; González-Moreno J; González-Pina B; López-Dupla M; Irurzun J;
Clin Microbiol Infect; 2009 Nov; 15(11):1046-50. PubMed ID: 19548926
[TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability of ertapenem versus ceftriaxone in a double-blind study performed in children with complicated urinary tract infection, community-acquired pneumonia or skin and soft-tissue infection.
Arguedas A; Cespedes J; Botet FA; Blumer J; Yogev R; Gesser R; Wang J; West J; Snyder T; Wimmer W;
Int J Antimicrob Agents; 2009 Feb; 33(2):163-7. PubMed ID: 18945594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
